The phosphorylation of histone H2AX in Serine 139 (gamma-H2AX) marks regions of DNA double strand breaks and contributes to the recruitment of DNA repair factors to the site of DNA damage. Gamma-H2AX is used widely as DNA damage marker in vitro, but its use for genotoxicity assessment in vivo has not been extensively investigated. Here, we developed an image analysis system for the precise quantification of the gamma-H2AX signal, which we used to monitor DNA damage in animals treated with known genotoxicants (EMS, ENU and doxorubicin). To compare this new assay to a validated standard procedure for DNA damage quantification, tissues from the same animals were also analyzed in the comet assay. An increase in the levels of gamma-H2AX was observed in most of the tissues from animals treated with doxorubicin and ENU. Interestingly, the lesions induced by doxorubicin were not easily detected by the standard comet assay, while they were clearly identified by gamma-H2AX staining. Conversely, EMS appeared strongly positive in the comet assay but only mildly in the gamma-H2AX immunofluorescence. These observations suggest that the two methods could complement each other for DNA damage analysis, where gamma-H2AX staining allows the detection of tissue-specific effects in situ. Moreover, since gamma-H2AX staining can be performed on formalin-fixed and paraffin-embedded tissue sections generated during repeated-dose toxicity studies, it does not require any further treatments or extra procedures during dissection, thus optimizing the use of resources and animals. Environ. Mol. Mutagen. 60:4-16, 2019.
INTRODUCTION
Safety assessment of pharmaceuticals, cosmetics, food ingredients, or industrial and agrochemical products requires a comprehensive assessment of their genotoxic potential. Generally, battery approaches are recommended by guidelines since no single test is capable of detecting all genotoxic mechanisms relevant in tumorigenesis (ICH S2(R2) 2012). For pharmaceutical products, in vivo models are included to evaluate genotoxic potentials in living organisms. The in vivo mammalian alkaline comet assay (OECD 2014a, TG489) has become a key tool, used in many cases as second in vivo assay in addition to the in vivo rodent micronucleus test (MNT), when an in vitro genotoxicity signal needs to be evaluated or to invest tumor-related pathological findings. However, both assays have their limitations: the MNT can only be performed in proliferating cells (blood or bone marrow cells in accordance with the guideline) (OECD 2014b, TG474) , while the comet assay, which can be executed in almost all organs, detects a transient effect (OECD 2014a, TG489, Annex 3). Due to DNA repair mechanisms, DNA damage can be detected by the comet assay only in a narrower time frame compared to the MNT. Both assays can be integrated into repeat-dose toxicity studies, but integration of the comet assay requires an additional treatment 2-6 hr before the dissection (Rothfuss et al., 2010; Rothfuss et al., 2011; Uno et al., 2015; OECD 2014a, TG489) , thus introducing an extra step into routine standard repeated-dose toxicity studies. In addition, depending on the mode of action (MoA) leading to genotoxicity, both assays have limitations in detecting the DNA damage. Thus, the development of additional in vivo methods to monitor organ-specific genotoxicity would be very desirable.
DNA double-strand breaks (DSBs) trigger the rapid phosphorylation of the histone protein H2AX in Serine 139, generating gamma-H2AX, which is one of the first steps in the recruitment of DNA repair proteins. Around the site of DSBs, histone proteins are rapidly phosphorylated over kilobase domains, principally by ATM (ataxia telangiectasia mutated), ATR (ATM-Rad3-related) and DNA-PK (DNA-dependent protein kinase). Gamma-H2AX itself can recruit other DSB signaling and repair factors to the site of damage, such as MDC1 (mediator of DNA damage checkpoint protein 1), 53BP1 (p53-binding protein 1) and the MRN (Mre11, Rad50 and Nbs1) complex. The cascade activated by H2AX phosphorylation induces DNA repair by nonhomologous end-joining (NHEJ) and homologous recombination (HR). After DNA is repaired, gamma-H2AX is dephosphorylated (Kuo and Yang, 2008; Shrivastav et al., 2008) . Gamma-H2AX is used widely as a DNA damage marker in vitro, since the availability of very specific antibodies allows its detection and quantification by ELISA (enzyme-linked immunosorbent assay), flow cytometry and immunohistochemistry/immunofluorescence (Watters et al., 2009; Nikolova et al., 2014) . In this manuscript, we evaluated the use of gamma-H2AX immunofluorescence (IF) for monitoring tissue-specific effects in vivo. Since gamma-H2AX staining can be performed on histopathological sections, genotoxicity readout of multiple organs/tissues could be readily integrated into general toxicity studies. In contrast to the comet assay or micronucleus test, no specific preparation of the organ is required, since paraffin blocks prepared for histopathology can be used. Besides the contribution to the reduction of animals (3R), an integrated measurement of genotoxicity endpoints also improves genotoxicity risk assessment, since the data can be evaluated in relationship with information from the repeat-dose toxicity study (e.g. histopathology, clinical chemistry, hematology) and exposure data. Furthermore, blocks of formalin-fixed paraffin-embedded tissues from former studies could be used to answer questions that arise later in the development, for example discrimination of genotoxic versus non-genotoxic effects to investigate carcinogenicity findings.
The objective of the current study was to evaluate gamma-H2AX immunofluorescent staining as a valid genotoxicity endpoint in situ. The emphasis of this study was a first method development -for both staining and quantification -for use in the genotoxicity testing strategy.
To compare gamma-H2AX staining versus the comet assay, rats were treated with strong genotoxic compounds (EMS, ENU, doxorubicin) showing different mechanisms of action. In order to test the reproducibility of the method, two independent studies were conducted. In addition to the 3-hour time point, which is requested by the OECD comet assay guideline (OECD 2014a, TG489), a second group of animals was dissected around 27 hr after the last dose, to investigate whether the DNA damage (either by comet assay or gamma-H2AX staining) could be detected up to the routine sampling time used in repeated-dose toxicity studies. The avoidance of additional treatment would facilitate integration into general toxicity studies and allow gamma-H2AX analysis in conventional paraffin-embedded organs.
The effects were assessed in the liver as the metabolically active organ for the compounds used, in the jejunum as site of first contact, and in the kidney that represents the excretory organ. In the comet assay, homogenates of whole organs/tissues are used. As a consequence, the mixture of different cell types does not allow the analysis of cell type-specific effects within one organ. In contrast, with the gamma-H2AX staining, DNA damage could be detected in situ in every single cell and in tissue-specific structures, such as crypts, villi and smooth muscle layers of the jejunum and cortex and medulla of kidney. Finally, since the manual scoring of the gamma-H2AX positive cells/foci is time-consuming and subject to operator variability, a reliable algorithm for signal quantification was concomitantly developed.
MATERIALS AND METHODS

Animal Husbandry and Treatment
Male Wistar rats [Crl:WI(Han)], about 8 weeks of age at the beginning of each experiment, were purchased from Charles River, Germany, and acclimatized for at least 5 days. The experiments were performed in line with the Swiss Animal Welfare Law (2008) and compliant with internal SOPs and guidelines for care and use of laboratory animals. Animals had access to pelleted standard rodent diet and tap water from the domestic supply ad libitum and were kept in an air conditioned animal room under periodic bacteriological control, at 22 AE 2 C with monitored 40%-80% humidity, a 12-hr light/ dark cycle, and background radio coordinated with the light hours.
Two independent studies were performed. Study A: Six rats per group were treated twice with an interval of 21 hr between the first and second administration ( Fig. 1 ) with oral doses of 50, 100 and 200 mg/kg/day EMS (ethyl methanesulfonate; CAS Number 62-50-0; Sigma Aldrich; USA, dissolved in water). Due to poor bioavailability when orally administered, doxorubicin was given as an intraperitoneal injection of 9 mg/kg/day doxorubicin hydrochloride (CAS: 25316-40-9; Alfa Aesar GmbH&CoKG Karlsruhe, Germany, dissolved in 0.9% sterile NaCl). Control groups were treated with an oral dose of 0.9% sterile NaCl. The dose levels of EMS were chosen based on published data of in house and international comet assay validation studies (Plappert-Helbig and Guérard, 2015; Rothfuss et al., 2011; Uno et al., 2015) . The doxorubicin dose level around MTD (maximum tolerated dose) was chosen based on published data (Hayward and Hydock, 2007; Shin et al., 2010) .
Three rats per group were sacrificed by carbon dioxide asphyxiation 3 or 27 hr after the last application. Samples from liver, kidney and jejunum were collected in HBSS-buffer (Hanks balanced salt solution) with 25 mM EDTA/10% DMSO; (Guérard et al., 2014) for the comet assay and fixed in 10% neutral buffered formalin (catalogue number HT5011, Sigma Aldrich, USA) for the gamma-H2AX staining.
Study B: In this second study, the number of animals/group was increased (4 instead of 3) and a third compound (ENU) was included. Since, in study A, only the highest dose of EMS (200 mg/kg/day) significantly induced gamma-H2AX, lower doses of EMS were not included in study B. The ENU dose level was chosen based on published data of an international comet assay validation study (Rothfuss et al., 2011) . Eight rats per group were treated twice with an interval of 21 hr between the first and second administration with an oral dose of 200 mg/kg/day EMS or 20 mg/kg/day ENU (ethyl nitrosourea; CAS Number 759-73-9; Sigma Aldrich, USA) or intraperitoneal injection of 9 mg/kg/day doxorubicin hydrochloride or an oral dose of 0.9% sterile NaCl (negative control group). Four rats per group were sacrificed 3 or 27 hr after the last application. The same procedure as for study A was applied for treatment, dissection and organ sampling.
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Comet Assay
Recommendations from different expert groups (Burlinson et al., 2007; Uno et al., 2015; Speit et al., 2015) and OECD guidance (OECD 2014a, TG489) were followed, along with an earlier published experimental protocol, including tissue choice and sampling, preparation of single-cell suspension and slides, followed by DNA unwinding, electrophoresis, neutralization of slides (Struwe et al., 2008; Guérard et al., 2014; Plappert-Helbig and Guérard, 2015) . Parts of liver, kidney and jejunum were sampled and processed for comet assay evaluation in accordance with the OECD guidance. Comet slides were stained with propidium iodide/20% Vectashield ® and analyzed within the ROBIAS image analysis systems (Novartis in-house development; Frieauff et al., 2001; Plappert-Helbig and Guérard 2015) . 
Gamma-H2AX Immunofluorescent Staining
Image Analysis
The slides were scanned with the Hamamatsu Nanozoomer at 40x magnification, using the scanner's fluorescence equipment to generate separate digital images for blue nuclear DAPI staining and green gamma-H2AX signal (FITC staining). The ImageScope software (V12.1.0.5029, Aperio Inc., USA) with an interactive pen tool for outlining regions of interest was used to manually draw annotation outlines within the tissue sample deemed suitable for subsequent image analysis ( Fig. 2A) . The operatordriven outlining guaranteed a controlled selection of the correct type of cells, for example by carefully keeping apart muscle, villi and crypts for jejunum. The exact spatial match of the green FITC and blue DAPI channels leaves the user with the choice of drawing in any of the two channel images, with the selection usually based on contrast and staining intensity of the cells. The resulting annotation file (xml format) was then also used for the other fluorescence channel to specify the identical region of interest in the second channel image.
Using an in-house developed ImageScope plug-in for the creation and export of *.tif images for each of the two fluorescence channels, matching pairs of image tiles (from DAPI and FITC channel) suitable for image analysis were created for the region annotations and stored accordingly.
A customized module to quantify the ratio of gamma-H2AX-positive nuclei over the total number of nuclei within the specified region of interest was developed as integration in a proprietary image analysis platform (ASTORIA, Automated Stored Image Analysis), running under MS Visual Studio 2010 and based on many tool functions and algorithms using Matrox MIL V9 libraries (Matrox Inc, Quebec, Canada) . No detailed listing or specification of the functions and modules is given since the Matrox MIL libraries consist of hundreds of low-level functions serving as a basis for more complex tool modules, mostly in the realm of Mathematical Morphology, that had been developed through the years.
For the image analysis of individual *.tif tiles, the following sequence of steps were performed. Details on the theoretical background of transformations using the concept of Mathematical Morphology, such as gradientwatershed or tophat transformation, are described in (Serra and Soille, 1994; Sternberg 1986 ).
For each fluorescence color tif image, the green (FITC) and blue (DAPI) channel were individually used as 8-bit gray images. First, valid nuclei were detected using the blue channel image only. For this purpose, several iterations of thresholded gradient-watershed transformations, using sequentially lowering threshold values, were computed. At each threshold level, the interior of the resulting binary object segmentation, based on the watershed lines from the current threshold, was analyzed with regard to morphometric features such as shape and average gray intensity. Using different filter limits for roundness, elongation, roughness, size and gray average on the blue channel, and looping through a range of meaningful thresholds, a collection of "valid" nuclei was sequentially built up. The process of selecting start and end threshold as well as cutoff values for used morphometric features was determined empirically. In a second run to catch the yet undetected bright nuclei, similar as the above, gradientwatershed was taken but now using the alternative concept of the tophat transformation to segment bright objects on a dark background, again using the filter criteria for morphometric object features. Again, through thresholding over a useful range of values, valid nuclei were collected at different contrast levels after passing the according morphometric filters. In the end, all but few faint or misshaped nuclei, most likely out of focus due to sectioning, were correctly segmented (Fig. 2 ). This two-tier segmentation approach (gradient-watershed and tophat transformations) was used for all organs. However, due to the different morphology of nuclei from different organs, different sets of parameter files with properly adjusted filter values were used for each organ. For the segmentation of the green gamma-H2AX signal, the green FITC channel image was used. Again, a tophat transformation to detect bright dots on a dark background was used. The rationale for computing a representative gray mean for the FITC signal was to eliminate bright small dots as well as larger very bright (green) regions as basis for a "gray mean computation". For this purpose, after identification of valid nuclei using the blue DAPI fluorescence channel, a morphological tophat transformation for detection of small bright dots in the green FITC channel was conducted, using a maximum size value of 10. Then the resulting tophat gray image was subtracted from the green channel image to obtain an image without small bright dots. Intensely bright green regions within this image were then masked out through thresholding, ignoring everything that exceed a fixed threshold (i.e. too intensely bright regions in the FITC channel). The average gray Fig. 1 . Treatment schedule of study A and B. Two independent studies (A and B) were performed. Groups of 6 rats (study A) or 8 rats (study B) were treated twice with an interval of 21 hr between the first and second administration. From each experimental group, half of the animals were sacrificed either 3 or 27 hr after the last application.
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The positivity threshold for binarization was then set to this computed gray average plus a fixed constant offset parameter (between 5 and 15, depending on the organ). Using this threshold value for binarization of the tophat image, sufficiently bright dots (in the green channel) were identified. By adding what had been masked out as "very bright" before, the final "green signal" image was obtained which then was restricted to valid nuclei, specifying the positive signal within individual nuclei.
The computed gray average, reflecting the mean signal in the FITC image outside small dots and large bright regions, served to determine a robust threshold for the tophat transformation and detection of small bright dots. Direct thresholding on the image was added to capture larger nuclei that escaped the tophat detection due to its size. By performing the Boolean OR operation on both approaches and restricting to previously determined valid nuclei, the gamma-H2AX-positive nuclei were specified. Besides counting positive and negative nuclei, the ratio of positive signal versus nuclear area was also reported for each nucleus, as well as the mean positive signal on the nucleus. No effort was made to distinguish between individual gamma-H2AX foci within the same nucleus, due to clustering, various sizes and smeared FITC staining, making a reliable discrimination of foci impossible.
Statistical Evaluation
The statistical analysis for the comet assay was performed with the standard procedure in accordance with the OECD guidance for the comet assay (OECD 2014a, TG489). For the data evaluated with the ROBIAS image analysis system, the individual %Tail Intensity value was log-transformed (log e) at the cell level. The median of the log-transformed values was used at the slide level. One hundred cells per slide were measured from two replicated slides. The arithmetic mean of all slides per animal was calculated and a one-way ANOVA was performed. In study A, a trend test (linear regression analysis with the negative control group and all treated groups) was used for the assessment of the linear dose-response relationship of EMS.
For the gamma-H2AX IF staining, the number of gamma-H2AX-positive cells over the total number of cells was quantified per slide (one slide/animal). The arithmetic mean of positive cells/1000 total cells was log-transformed (log e). For each experimental group, normal distribution and variance homogeneity were assessed, respectively, with a Shapiro-Wilk and a BrownForsythe test. Differences between test compounds and the negative controls were therefore assessed with a one-way ANOVA. For all organs, the difference between groups was defined as significant for P ≤ 0.05 and highly significant for P ≤ 0.01. Statistical analysis was performed with GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Comet Assay
In both studies A and B, no signs of toxicity or relevant reduction in body-weight gain were seen in the negative control or test compound-treated groups. EMS and ENU (Tables I and II) in jejunum, kidney and liver. EMS-induced dose-related statistically significant increases in %Tail Intensity (%TI) at 50, 100 and 200 mg/kg/day in study A. DNA damage starting at 50 mg/kg/day EMS was observed 3 hr after treatment but unexpectedly still persisted 27 hr after treatment (Table I) . This result was confirmed in the second independent study (study B, Table II) using 200 mg/kg/day EMS only. ENUinduced statistically significant increased %TI above control levels 3 hr after treatment but also 27 hr after treatment (study B, Table II ). Doxorubicin did not induce significantly elevated %TI in jejunum, kidney or liver in study A (Table I) , whereas significant elevated levels were obtained in the second study (Table II) for kidney (only after 3 hr) and liver (both time points). The inconsistency between repetitions suggests that the lesions induced by doxorubicin cannot be easily quantified by the standard comet assay, which can detect a broad spectrum but not all types of DNA damage (OECD 2014a, TG489). Indeed, the standard protocol for the in vivo mammalian alkaline comet is not particularly suited for lesions such as DNA cross-links or bulky DNA adducts. This could explain why this approach is not very sensitive in detecting DNA damage induced by doxorubicin.
In order not to miss the genotoxic effect of such compounds, the genotoxicity panel should contain a simple test system that provides convincing information on DNA DSBs in different organs. Therefore, the same organs were investigated in the gamma-H2AX assay. This approach provides the unique opportunity to analyze DNA damage in the native tissue context and to detect cell-type specific effect, which is not feasible with methods where tissue structures are destroyed. Further, a method that utilizes histopathological tissue sections could be integrated into routine toxicity studies or acute combined comet assay studies, as it allows the storage and analysis of the samples at later time points.
Gamma-H2AX Immunofluorescence
In study A (Table III) , doxorubicin induced a statistically significant increase in the levels of gamma-H2AX-positive cells in all the organs analyzed, at both time points. In contrast, EMS did not induce statistically significant increase in gamma-H2AX-positive cells in liver and kidney. Interestingly, in jejunum, statistically significantly elevated levels of gamma-H2AX stained cells were observed in the crypts after treatment of 200 mg/kg/day EMS. For an organ-or tissue-specific analysis of treatment-related effects, the fold increase (FI) was calculated for each tissue. Since the effects with 200 mg/kg/day EMS were minor, the organs from 50 mg/kg/day or 100 mg/kg/day treated groups were not evaluated for gamma-H2AX staining.
In study B, (Fig. 3 , Table IV ) it was confirmed that doxorubicin induced statistically significantly elevated levels of gamma-H2AX-positive cells in liver, jejunum (Fig. 4) and kidney after 3 and 27 hr. Also, the absence of gamma-H2AX induction was confirmed in the liver and in the muscularis layer of the jejunum in EMS-treated animals. In the jejunum crypts, EMS induced in one out of three experiments a statistically significantly increase in gamma-H2AX-positive cells (Figs. 3 and 4) . However, a statistically significant increase in gamma-H2AX-positive cells was found in the kidney (Fig. 3, Table IV ). In this second study, the analysis was extended to the villi, which also proved positive (Figs. 3 and 4) .
In contrast to EMS, treatment with 20 mg/kg/day ENU induced statistically significantly elevated levels of gamma-H2AX-positive cells in the muscularis layer and the crypts of the jejunum. Furthermore, ENU induced statistically Groups of six rats were treated with an oral dose of NaCl (control group, Ctrl), oral doses of EMS or intraperitoneal injection of doxorubicin (Doxo). Twenty-one hours later, the same treatment was repeated in each group. Animals (3/group) were sacrificed 3 or 27 hr after the second treatment. A portion of each organ was processed for the comet assay; another portion was fixed in formalin for subsequent gamma-H2AX staining (Table III) . Statistical significance was evaluated with ANOVA and t-test *P ≤ 0.05 (no difference was observed for statistical significance between ANOVA and t-test).
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In general, with the exception of jejunum villi, in all tissues, all three drugs analyzed induced gamma-H2AX, though with a different intensity. The highest DNA damage was observed with doxorubicin followed by ENU, whereas EMS induced no/minimal increase.
Tissue-specific DNA damage could be clearly demonstrated in the muscularis layer of the jejunum (Figs. 3 and  4) , where the proportion of gamma-H2AX-positive cells increased to ≥60% after treatment with doxorubicin. In general, the percentage of gamma-H2AX-positive cells was higher at 3 hr than at 27 hr after treatment. Moreover, similar to the trend observed in the comet assay, differences between the control and the 27 hr group were still significant. For instance, in tissues from EMS-treated animals, gamma-H2AX levels after 27 hr were comparable or even higher than after 3 hr. In conclusion, in our limited experimental setting, DNA damage was still efficiently detected after 27 hr. However, the small number of compounds analyzed is not sufficient to draw a final conclusion on the possibility to exclusively use the 27 hr time point.
In order to test the reproducibility of the results, two different experiments, in which sections of organs were taken from animals treated in independent studies, were carried out (study A and B, Tables III and IV). The absolute levels of gamma-H2AX-positive cells varied between studies A and B: for example, in study A, the basal levels for liver Groups of eight rats were treated with NaCl (control group, Ctrl), doxorubicin, EMS or ENU. Twenty-one hours later, the same treatment was repeated in each group. Animals (4/group) were sacrificed 3 or 27 hr after the second treatment. A portion of each organ was processed for the comet assay; another portion was fixed in formalin for subsequent gamma-H2AX staining (Table IV) . Statistical significance was evaluated with ANOVA and t-test *P ≤ 0.05 (no difference was observed for statistical significance between ANOVA and t-test). 
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Groups of six rats were treated with an oral dose of NaCl (control group, Ctrl), an oral dose of EMS or intraperitoneal injection of doxorubicin. Twenty-one hours later, the same treatment was repeated in each group. Animals (3/group) were sacrificed 3 or 27 hr after the second treatment. A portion of each organ was processed for the comet assay (Table I) ; another portion was fixed in formalin for subsequent gamma-H2AX immunofluorescence staining. Liver, kidney (cortex and medulla) and jejunum (crypts and muscle) were analyzed. The number of gamma-H2AX-positive cells over the total number of cells (expressed as ‰ γH2AX +ve cells) was quantified with the image analysis system. The fold increase (FI) was calculated for a transparent comparison. Organs from 50 mg/kg/day or 100 mg/kg/day treated groups were not evaluated for gamma-H2AX staining. *Statistically significant increase vs. control (P ≤ 0.05). # Statistically significant increase vs. control (P ≤ 0.01).
Environmental and Molecular Mutagenesis. DOI 10.1002/em were 6-to 10-fold lower than in study B, which was an important learning toward the reproducibility of the assay. This discrepancy could be due to differences in the experimental procedure and/or biological variability. However, this variation is not affecting the final outcome since the fold increase in gamma-H2AX positivity induced by the different drugs in different tissues matches among the two studies. To test inter-and intraexperimental variability, slides from study B were stained on different days with different batches of reagents (experiments 1 and 2). To test the influence of the manual outlining procedure used during image analysis (methodology described in Material and Fig. 3 . Gamma-H2AX immunofluorescence staining results of study B (experiment 2y). Tissue slides from animals treated as described in Table IV were stained for gamma-H2AX.The number of gamma-H2AX-positive cells over the total number of cells (expressed as ‰ γH2AX +ve cells) was quantified with proprietary image analysis software in liver, kidney (cortex and medulla) and jejunum (crypts, muscle and villi). Bars represent SD.
Environmental and Molecular Mutagenesis. DOI 10.1002/em Methods and in Fig. 2 ), two slides from each sample/group were stained on the same day with the same reagents, but the outlining was performed by two different experimenters (experiment 2x and 2y). The fold increases (Table IV) indicated good test reproducibility for all organs. The general concordance in the trend observed in all the repetitions (with different reagents and with different operators) supports the robustness of the method.
DISCUSSION
Genotoxicity assessment is usually done using batteries of test systems and different endpoints. Often, in vitro tests, which sensitively detect signals of a genotoxic activity, are followed up by in vivo tests to characterize those effects and to evaluate their relevance. Recently, particularly in the drug development field, it has become widespread practice to combine several endpoints into the same study. For example, a recommended combination for that purpose is the acute peripheral blood or bone marrow micronucleus test in parallel with the comet assay. In order to reduce animal usage but also to obtain very data-rich information from the same study, ancillary tests should be integrated into general repeated-dose toxicity studies, which are conducted anyway. A shortcoming of this approach is the fact that the comet assay generally requires the treatment and sampling within a relatively short and defined time window, which complicates integration into other studies. Further, since homogenates of tissues are used, the analysis of cell type-specific effects within one organ is not readily possible. Gamma-H2AX staining, which can be performed on tissue sections, promises to overcome those limitations. Thus, in order to evaluate whether the gamma-H2AX IF could be a useful tool to extend this genotoxicity test panel, a comparison with the current gold standard method -the 
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Groups of eight rats were treated with NaCl (control group, Ctrl), EMS, doxorubicin, or ENU. Twenty-one hours later, same treatment was repeated in each group. Animals (4/group) were sacrificed 3 or 27 hr after the second treatment. A portion of each organ was processed for the comet assay (Table II) ; another portion was fixed in formalin for subsequent gamma-H2AX immunofluorescence staining. Liver (Table IVa) , kidney (cortex and medulla, Table IVb-c), and jejunum (crypts, muscle and villi, Table IVd-f ) were analyzed. The number of gamma-H2AX-positive cells over the total number of cells (expressed as ‰ γH2AX +ve cells) was quantified with the image analysis system. The fold increase (FI) was calculated for a transparent comparison. Experiment 1 and 2 were run with different batches of reagents in different days. Experiment 2x and 2y were run with the same batches of reagents and in parallel starting from different slides (consecutive sections of tissue). *Statistically significant increase vs. control (P ≤ 0.05). # Statistically significant increase vs. control (P ≤ 0.01) Environmental and Molecular Mutagenesis. DOI 10.1002/em comet assay -was conducted. Two independent studies, using the genotoxicants EMS, ENU and doxorubicin, were performed and the results obtained with the comet assay and gamma-H2AX staining were compared. In the first study (Study A), three different dose levels of EMS were used in order to define the dose-response of the effect, whereas one dose level of doxorubicin was used to include a compound with a different MoA. The second study (Study B) was conducted to (a) assess reproducibility of the results obtained, (b) to include a third compound (ENU) with known MoA, and (c) to increase the statistical power by incrementing of one unit the number of animals/ group (4 instead of 3). In the comet assay, EMS and ENU induced statistically significant increases in DNA damage 3 and 27 hr after treatment (Tables I and II) . As an unexpected finding of this study, we were able to demonstrate that EMS-induced DNA damage is still detectable even 27 hr after treatment. This was a remarkable observation since the %TI values determined after 27 hr were only slightly lower than at 3 hr, and highly significantly increased over the concurrent negative controls. Total plasma clearance of EMS in rats was described as 2.32 mL/min/kg and plasma half-life was roughly 120 min (Lavé et al., 2009a , Lavé et al., 2009b . Therefore, our data suggest a slow repair in vivo: since the exposure of EMS after 27 hr is negligible (Lavé et al. 2009a , Lavé et al. 2009b , the DNA strand breaks measured in the comet assay are plausibly not arising from a persistent exposure, but more likely due to a delayed repair. However, it is generally expected that DNA repair will remove the DNA damage from alkylating agents within hours; therefore, the OECD guideline (OECD 2014a, TG489) requests the last treatment not earlier than 2-6 hr before dissection. Our results indicate that there are examples where this may not be necessary, and a 24-27 hr time point after the last treatment could be informative. Further studies are required to investigate the usefulness of the comet assay at later time points, and to investigate if the persistance of DNA damage is linked to the specific mode of action of a given compound.
Since the result of the first study (Study A) confirmed the influence of the type of DNA breaks (single versus double strand breaks) on the detection limit of both assays, in the second study (Study B) an additional compound (ENU), with a mixed MoA, was included. EMS and ENU are directly acting alkylating agents that have been found to be genotoxic in a wide variety of genetic test systems from bacterial mutation test to mammalian cell assay in vitro and/or in vivo (Morita et al., 2015; Doak et al., 2007) . EMS induces mostly DNA single strand breaks (SSBs), but almost Environmental and Molecular Mutagenesis. DOI 10.1002/em no double-strand breaks (DSBs) (Bradley and Dysart, 1985; Beranek, 1990) . In contrast, ENU induces similar numbers of DNA SSBs and DSBs both in vitro and in vivo (Bradley and Dysart, 1985; Beranek, 1990) . Doxorubicin is an antineoplastic drug that has been used for treating cancer for over 30 years but it is also known to induce DNA damage in various cell types. On the molecular level, a number of different mechanisms have been proposed for the cytotoxic and genotoxic MoA of doxorubicin. These include intercalation into DNA, free radical formation with consequent induction of DNA damage, DNA binding and alkylation, DNA cross-linking, interference with DNA unwinding or DNA strand separation and helicase activity, and the initiation of DNA damage via the inhibition of topoisomerase II (Gewirtz, 1999; Cutts et al., 2005; Simunek et al., 2009; Tacar et al., 2012; Yang et al., 2014) . However, the mechanisms that were proposed remain controversial. Thus, doxorubicin is a good tool compound for drugs with a large spectrum of activity including genotoxicity, which needs to be detected in the in vivo genotoxicity testing battery.
Doxorubicin did not induce significant DNA damage as measured by the comet assay in study A (Table I) , whereas statistically significant DNA damage was observed in liver and kidney in study B (Table II) . This result is in accordance with Manjanatha et al. (2014) : the authors did not find any DNA damage in the standard comet assay in heart, kidney, liver, testis nor blood after a cumulative dose of 12 mg/kg (4 single doses of 3 mg/kg on 4 days). However, with a modified comet assay based on the use of lesionspecific endonucleases, specifically developed for sensitive detection of oxidative lesions (Collins, 2004) , DNA damage could be detected in heart, kidney and liver (Martins et al., 2012) . The negative response of study A and the study of Manjanatha et al. (2014) is in contrast to the positive response of Martins et al. (2012) and our study B. The values in study A were elevated (increase in %TI: kidney 1.2 fold/ liver 1.3-fold) but not statistically significant, while in study B -where the number of animals/group was increased to improve the statistical power -doxorubicin did induce significant DNA damage in kidney and liver (increase in %TI: kidney 1.5-fold/ liver 2.6-fold). The discrepancy between studies could also be due to the differences in the doses administered: Martins et al. (2012) used a higher single dose of doxorubicin (15 mg/kg) than Manjanatha et al. (2014) .
This shows that the lesions induced by doxorubicin cannot easily be detected by the standard version of the comet assay, which is due to the nature of the damage. The standard protocol for the in vivo mammalian alkaline comet assay detects a broad spectrum of DNA damage (OECD 2014a, TG489) . However, it is not suited for DNA crosslinking agents, which are characterized by a decrease in DNA migration. Furthermore, DNA damage induced by bulky DNA adducts is not reliably detected in the standard comet assay and might be missed (Speit et al., 2015 , Collins, 2004 . In addition, there is evidence that a key component of the mechanism of action of doxorubicin is the effect as a topoisomerase II poison (Yang et al., 2014) . Once intercalated into DNA, it disturbs the re-ligation step of topoisomerase II resulting in the formation of DNA DSBs to an extent which should be detectable in the comet assay. In summary, for doxorubicin, the cross-linking activity with decrease in DNA migration and DNA stand break induction by repair, and finally topoisomerase inhibition can generate opposing trends in the principle of detecting DNA damage by electrophoretic migration in the comet assay, thereby preventing a consistent detection by this assay.
In order to assess the genotoxic effect of such compounds, the genotoxicity testing panel should contain a simple test system that provides convincing information on DNA DSBs on the organ level. Therefore, the same organs were investigated by gamma-H2AX IF staining. The increase of gamma-H2AX-positive cells at the dose level used in these studies was highly significant for doxorubicin and more pronounced with ENU compared to EMS (Fig. 3 , Table IV ). In contrast, in the comet assay, the DNA damage was lower for ENU compared to EMS (Table I ) and even no detectable or equivocal for doxorubicin. This suggests that compounds that induce DSBs could be detected with much higher sensitivity performing gamma-H2AX IF rather than the comet assay, which supports the initial hypothesis that the amount of DNA SSBs/DSBs influences the sensitivity of both assays.
The gamma-H2AX IF has the advantage to detect DNA damage in intact organs, which allows the precise localization of genotoxic effects. To explore compartment-specific effects in situ, crypts, villi and smooth muscle in the jejunum, and cortex and medulla in the kidney were analyzed separately. Of note, doxorubicin induced a higher proportion of gamma-H2AX-positive cells in jejunum smooth muscle compared to crypts or villi. This is in line with preclinical observations that doxorubicin treatment is associated with dysfunction of skeletal muscle (Gilliam et al., 2009 ) and cardiotoxicity in rats and mice (Hayward and Hydock, 2007; Childs et al., 2002) , as well as the known clinical observation of muscular pain and dysfunction in doxorubicin-treated patients (Gilliam and St. Clair, 2011; Hayward et al., 2013) . The most severe symptoms are found in cardiac tissue, but skeletal and aortic smooth muscle also show significant dysfunction (Hayward et al., 2013) . According to our data, the jejunum smooth muscle can also be regarded as a toxicity target tissue of doxorubicin. One of the postulated main mechanisms of doxorubicin's muscle toxicity is oxidative stress. Oxidant-mediated apoptosis is a known MoA in skeletal muscle atrophy, leading to caspase activation (Arthur et al., 2008; Tacar et al., 2012) .
Differently from doxorubicin, EMS did not significantly increase gamma-H2AX positivity in the smooth muscle layer in the jejunum, while ENU only slightly affected it, Environmental and Molecular Mutagenesis. DOI 10.1002/em thus showing the peculiarity of the DNA damage induced by doxorubicin. Doxorubicin, EMS and ENU all induced gamma-H2AX-positive cells in the kidney. However, there were no major differences between medulla and cortex.
Another not unexpected finding of our studies was that each tissue has its own basal value of DSBs. In the control group, the basal levels of gamma-H2AX for the jejunum crypts are higher than for the other tissues. The stem cells at the base of intestinal crypts are continuously proliferating to regenerate the intestinal mucosal epithelium. They differentiate into multiple functionally distinct epithelial subtypes, which then migrate upward to the villus tips (Parker et al., 2017) . It has been shown that gamma-H2AX foci exist in parallel to replication fork breakage in the S phase, which indicates the presence of gamma-H2AX positivity in dividing cells . The relatively small staining increase induced by all compound in the jejunum crypts could be explained by the high gamma-H2AX basal levels in the proliferating stem cells, which could conceal the additionally induced DNA breaks.
Despite the limited experimental setup used in our studies, the data indicate a good reproducibility of the gamma-H2AX IF staining. There is variability in the intensity of the gamma-H2AX signal, probably due to differences in the batches of reagents used in all the steps of the procedure (from fixative to secondary antibodies). Moreover, as in any in vivo experiment, there is variability between animals. However, in our experience, four animals/group were sufficient to assess differences between experimental groups. Further studies are required to identify the ideal number of animals to be treated and the number of slides to be measured from each animal. Although a broader validation with different compounds is required to assess the use of the gamma-H2AX IF as complement to the standard battery tests, our pivotal study strongly suggests its potential for improving genotoxicity assessment in vivo. In conclusion, the routinely used standard battery of genotoxicity tests may provide contrasting, equivocal or even negative responses when the genotoxic activity of the compound depends on tissue-specific mechanisms, and the comet assay gives only results on the complete tissue unless there is significant enrichment, for example by separating cell types before analysis. Still then, in no case, the assay could monitor the genotoxic load of cells in the natural tissue context, which is instead provided in the gamma-H2AX IF staining as used in our experiments. Therefore, to evaluate the genotoxic effect in vivo, the gamma-H2AX IF staining is an ideal test to supplement the package for genotoxicity testing.
